Susan Berson and Brent Henry Recognized as Health Care Trailblazers by the National Law Journal
Filter by:
Member Jeffrey Moerdler was quoted in a Broadband Breakfast article about a recent panel he participated in titled "Where and How Can We Meet the Demand for Data Centers." According to panelists, mid-market data center operators are finding notable growth opportunities serving enterprise AI demands. They also discussed the power constraints affecting mid-market operators.
Mintz Appoints Head of Innovation, AI, and E-Data Consulting
March 24, 2025
Mintz announces the appointment of John B. Koss as Head of Innovation, AI, and E-Data Consulting. Drawing on over 20 years of legal and technology experience, John will lead Mintz’s efforts in exploring how the firm can use AI and other emerging technologies to further advance client service and operational efficiency.
Mintz Advises Lightkeeper in Growth Investment from PSG
March 21, 2025
Mintz advised Lightkeeper, a leading provider of data, analytics, risk management, and reporting solutions for investment managers, in a growth investment from PSG, a growth equity firm focused on software and technology-enabled services companies.
Three Mintz Members have been selected to serve on Law360’s 2025 Editorial Advisory Boards in their respective practice areas. The editorial advisory boards provide feedback on Law360’s coverage and expert insight on how best to shape future coverage.
Why Did the SEC Remove the Enforcement Director’s Authority to Issue Formal Investigations? Sources Have Different Ideas.
March 18, 2025
Member David Adams was quoted by Pensions & Investments in an article about the SEC’s recent decision to eliminate the enforcement director’s authority to issue formal investigations. The article explores the significance and implications of the shift, including how crypto comes into play.
The Pros and Cons of Self-Disclosure: Q&A With Karen Lovitch
March 14, 2025
Health Care and Health Law Practice Chair Karen Lovitch was featured in a Q&A by Laboratory Economics about the pros and cons of companies and clinical labs self-disclosing potential civil and criminal violations.